PRECISION
Ongoing study Official Study Title Safety and efficacy of Anakinra treatment for patients with Persistent REspiratory symptoms post-acute COVID and Immune System activatION: the PRECISION double-blind, randomized clinical trial Brief Description The effect of the drug anakinra in the treatment of long-term complications after COVID-19. The PRECISION is a proof-of-concept, phase II randomized clinical
HDM-FUN-Candidemia
Ongoing study Official Study Title Safety and Efficacy of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Candidemia: The HDM-FUN-Candidemia trial Brief Description Invasive fungal infections are an important cause of morbidity and mortality and lead to numerous hospital and ICU admissions. Candidemia is associated with a suppressed immune status
INSPIRE
Ongoing study Official Study Title Immunotherapy Navigated by Serum Presepsin for Infections of the REspiratory tract: the INSPIRE double-blind, randomized, phase IIa exploratory trial Brief Description The INSPIRE study is an exploratory, randomised, phase IIa clinical trial which aims to evaluate the potential benefit of presepsin-guided anakinra therapy as an adjuvant to the standard
H4COVID
Ongoing study Official Study Title Hydrogen Sulfate guided therapy with STS for COVID-19 patients in need of Critical Care: The H4COVID open-label, randomized, triple-arm trial Brief Description H4COVID open-label study is aiming to describe the safety of administration of three doses of STS to critically ill patients with confirmed COVID-19. Details Status: Recruiting
BEYOND
Completed study Official Study Title Bezlotoxumab Υielded Οutcomes by addressing personalized Needs in Clostridioides Difficile infection: the BEYOND double-blind randomized clinical trial Brief Description Previous data from our group have shown that integrated information from SNPs of the host DNA, IL-8 and the enrichment of the stool microbiome can indicate the patients with infection
ImmunoSep
Ongoing study Official Study Title Personalized Immunotherapy in Sepsis: a multicentre and multinational, double-blind, double-dummy randomized clinical trial Brief Description Previous findings coming from the randomized clinical trial PROVIDE have showed that serum ferritin and expression of HLA-DR on circulating monocytes are reliable diagnostic markers of macrophage activation syndrome and of sepsis-induced immunoparalysis. The